NCT05722522 - Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 10, 2023

Primary Completion Date

October 18, 2024

Study Completion Date

December 13, 2024

Conditions

Rotator Cuff Tendinopathy

Interventions

DRUG

Secukinumab

The participants will receive Secukinumab 300 mg s.c. at randomization (Baseline visit), Week 1, 2, 3, 4, 8, and 12

DRUG

Placebo

The participants will receive placebo s.c. at randomization (Baseline visit), Week 1, 2, 3, 4, 8, and 12

Trial Locations (15)

Novartis Investigative Site, Sofia

Novartis Investigative Site, San Miguel de Tucumán

West Clinical Research, Morehead City

Healthy Life Research, Miami

IRIS Research and Development, Plantation

Precision Clinical Research LLC, Sunrise

West Tennessee Research Institute, Jackson

Novartis Investigative Site, Brno

Novartis Investigative Site, Kota Kinabalu

Millennium Clinical Trials, Westlake Village

Novartis Investigative Site, Buenos Aires

Novartis Investigative Site, Québec

Novartis Investigative Site, Kolín

Novartis Investigative Site, Ponte de Lima